Concepedia

Novel and potent calcium-sensing receptor antagonists: Discovery of (5R)-N-[1-ethyl-1-(4-ethylphenyl)propyl]-2,7,7-trimethyl-5-phenyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide monotosylate (TAK-075) as an orally active bone anabolic agent

Masato Yoshida, Akira Mori, Shinji Morimoto, Etsuo Kotani, Masahiro Oka, Kohei Notoya, Haruhiko Makino, Midori Ono, Mikio Shirasaki, Norio Tada,

Bioorganic & Medicinal Chemistry · 2011 · 11 citations · 14 references

DOIFull text

Open access

Concepts

References

14

Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis

Robert M. Neer, Claude D. Arnaud, José Zanchetta et al. · New England Journal of Medicine · 2001 · 4.6K citations

, , +16

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures

Dennis M. Black, Steven R. Cummings, David Karpf et al. · The Lancet · 1996 · 3.9K citations

, , +12

Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With Raloxifene<SUBTITLE>Results From a 3-Year Randomized Clinical Trial</SUBTITLE>

Bruce Ettinger · JAMA · 1999 · 3.4K citations

, , +17

Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal Osteoporosis

Jean‐Yves Reginster, H. W. Minne, O. H. Sørensen et al. · Osteoporosis International · 2000 · 1.6K citations

, , +14

Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats

Maxine Gowen, George B. Stroup, Robert A. Dodds et al. · Journal of Clinical Investigation · 2000 · 278 citations · Full text

, , +17